Cancer Treatment for Everyone

Company Mission

Massive Bio is driven to provide cancer patients, their families and trusted treating oncologists, a service that will generate the most up-to-date precise oncology plan without disrupting their lives, relocating or financially hindering them.

Our Story

In 2014, CEO and founder of Massive Bio, experienced first-hand a loved one diagnosed with cancer, her uncle was diagnosed with cancer. During this devastating time, Selin Kurnaz realized the lack of available information and data that her uncle’s oncologist had and those in the hospital. This set Ms. Kurnaz on a mission, starting first with researching why treating oncologist were unable to access information about current aggressive clinical trials and immunotherapies and their results.

A major discovery was that people in rural areas, about 50 miles from any recognized cancer treatment center, were most effected by three common factors. First, their treating oncologist were seeing so many patients that they did not have time and/or the advance technology available to identify and develop precise treatment opportunities based on new research and trials performed around the world. Secondly, patients and their families were being financially burdened due to travel, treatments, lodging, etc. The third factor was time. The treating oncologist did not have time to research specific cancers, the patients did not have time to wait for results that had to be sent away for further testing and cancer continued to grow and spread.

The outcome of this research, was the idea of a virtual tumor board, the use of algorithms and teaming with patients and their treating oncologists. If the Virtual Tumor Board, a group of esteem top oncologist could review data, the patient’s history, the algorithm that identified the cancer with others and their outcomes, plus their own experiences, then they could devise a comprehensive short list of options that would be as precise and personalized as any large cancer treatment facility. The last step, as it began with the first step of the process, was with the patient. Ms. Kurnaz didn’t want the patient to travel extensively, waste valuable time or money. So instead of having patients leave a trusted oncologist, Massive Bio would join their team and go to them.

Today, Massive Bio brings the best of two worlds together; top oncologist from around the world and cancer patients who otherwise might miss the opportunity to improve their quality of life.

Watch Our Journey with Cancer Patients
Massive Bio Global Oncologist Team
Watch this video for more information on Massive Bio

Executive Team

Massive Bio's multidisciplinary team is strong and rising, consisting of oncologists, molecular diagnostic scientists, reimbursement experts and data scientists. Here are a few of our key members.

Selin Kurnaz, PhD
Chief Executive Officer
Dr. Kurnaz is an expert in strategy, operations and transactions with a unique, global background that spans across healthcare, academia and consulting. After completing a PhD at the University of Michigan and receiving multiple engineering degrees, Dr. Kurnaz spent more than a decade delivering revenue enhancement, margin optimization and capital efficiency improvements for Pharmaceutical and Life Science companies. Dr. Kurnaz also has measurable success identifying and delivering value to over a dozen investment firms. Most recently, Dr. Kurnaz was with EY's Private Equity Value Creation. Dr. Kurnaz has also written and spoke extensively about improving customer responsiveness in disruptive times.
Dr. Arturo Loaiza-Bonilla
Co-founder and Chief Medical Advisor
Dr. Loaiza-Bonilla is an ABIM certified specialist in Medical Oncology, Hematology and Internal Medicine. He has extensive clinical and research experience with a focus in precision oncology and translational-based trials, as well as the multidisciplinary comprehensive care of patients suffering from gastrointestinal and neuroendocrine malignancies. Using evidence-based and patient-centered approaches, Dr. Loaiza-Bonilla integrates next-generation personalized molecular diagnostics, immunotherapy, comorbidity, previous therapies, and the patient's overall status into decision making. Dr. Loaiza-Bonilla also provides expert second opinions (locally and internationally), clinical trial guidance, as well as recommendations regarding the integration of personalized cancer genomics, biosimilars, pharmacoeconomics and the concomitant use of complementary/integrative medicine.

Dr. Loaiza-Bonilla is principal and co-investigator on several Phase I/III cancer clinical trials with an emphasis on new targeted therapies, novel molecules and immunotherapy tailored to specific tumor type, genomic and protein expression profiles. Dr. Loaiza-Bonilla is a passionate advocate for precision oncology, medical education, organized medicine leadership and global health policy. Dr. Loaiza-Bonilla has been awarded the AMA Foundation Leadership Award and the Fellowship of the American College of Physicians. In addition, Dr. Loaiza-Bonilla holds a Master in Medical Education (M.S.Ed) degree from the University of Pennsylvania.
Belisario A. Arango
Dr. Belisario A. Arango
Chief of Community Oncology
Dr. Belisario A. Arango is the medical director of the Cancer Center and the Coagulation/Thrombosis Clinic at Chippewa County War Memorial Hospital and is affiliated with Helen Newberry Joy Hospital and Mackinac Straits Hospital and Health Center. In addition, Dr. Arango serves as director of the Continuing Medical Education for providers at War Memorial Hospital. As a solo practitioner, Dr. Arango specializes in providing both hematology and medical oncology care for the majority of patients who reside in the Eastern Upper Peninsula of Michigan. Prior to completing his internal medicine residency and hematology/oncology fellowship, Dr. Arango completed 2 years of medical oncology research at The University of Miami Sylvester Comprehensive Care Center/Jackson Memorial Hospital with a focus on genitourinary malignancies and sarcomas. Dr. Arango has authored multiple articles in peer-reviewed journals and has presented at international medical oncology conferences.

Dr. Arango practices evidence-based medicine and believes that cancer care requires a multi-disciplinary team approach. In an era of rapid developments in cancer care knowledge, Dr. Arango has been instrumental in bringing precision medical oncology care to patients at community hospitals that was otherwise inaccessible to them unless they were evaluated at a tertiary institution. Dr. Arango’s philosophy is to take care of cancer patients as if they were his own family members. He goes above and beyond what is necessary to deliver optimal and state of the art cancer care for his patients by utilizing medical technology and collaborating with different institutions in the region.
Dr. Jason L. Freedman
Chief Pediatric Advisor
Jason Freedman, MD, MSCE is a Board Certified Pediatric Oncologist who graduated with honors from Cornell University and received his medical degree Magna Cum Laude from Upstate Medical University in Syracuse, NY. Dr. Freedman completed his residency in Pediatrics at the Children’s Hospital of NY-Presbyterian (Columbia University) and served as Pediatric Chief Resident, thereafter. He completed fellowship training in Pediatric Hematology/Oncology at Children’s Hospital of Philadelphia (CHOP), during which time he earned a Master’s of Science in Clinical Epidemiology (MSCE) from the University of Pennsylvania.

Dr. Freedman has received numerous awards and honors including induction into the Alpha Omega Alpha medical honor society, and nominations into the President’s Circle of Excellence and Attending of the Year at the Children’s Hospital of NY-Presbyterian. During fellowship at The Children’s Hospital of Philadelphia, he was the recipient of the William Potash Fellow Teacher of the Year for his commitment to resident education and clinical excellence. As a faculty member at PENN/CHOP, he has earned a Distinguished Teaching Award and was selected for the early career faculty honor roll.

Dr. Freedman is an attending physician in Oncology at CHOP, where he also has administrative and teaching responsibilities. Dr. Freedman’s clinical focus is blood and marrow transplantation and hematologic malignancies. He has a particular interest in quality improvement and supportive care, and serves on several national committees. Dr. Freedman has authored several textbook chapters and peer-reviewed articles on the care of children with cancer and has contributed to the development of clinical guidelines to standardize management of symptoms associated with cancer therapy.
Cagatay M. Culcuoglu
Co-founder, Chief Operating Officer & Chief Technology Officer
Mr. Culcuoglu leads operational strategy, global business initiatives, product and technology development at Massive Bio. Mr. Culcuoglu has developed several products over the past 20 years, primarily for the financial, media and health industry. A serial entrepreneur, Mr. Culcuoglu co-founded startups, where he also led business and sales operations as well technology and product development. Mr. Culcuoglu took senior roles at Thomson Reuters, Mubasher, KPMG, Sabrient Systems, Anadolu Agency, Merrill Lynch and Smeal College.

Mr. Culcuoglu is an active board member in multiple start-ups and an owner of a media company. In addition, Mr. Culcuoglu holds an MBA degree from Pennsylvania State University and MA degree from University of Maastricht.

Scientific Advisory Board

Massive Bio’s scientific advisory board provides subject matter expertise as it relates to the current treatment practices for cancer and how they may be evolving. Our board evaluates:

  • Current treatment decisions on the selection of chemotherapy, backbones/biologics, and the sequencing of therapies based on recent data from world scientific meetings (ASCO, ESMO, AACR, etc.)
  • Patient selection and approach towards personalized treatment with respect to tumor profiling and biomarker assessment.
  • Economic analyses of cancer and how real world data (RWD) studies looking at effectiveness and costs would factor into treatment paradigms.
  • The role of immunotherapy checkpoint inhibitors in cancer and other immune-oncology approaches in development.

maurie markman
Maurie Markman
Maurie is a nationally renowned oncologist and has more than 20 years of experience in cancer treatment and gynecologic research at some of the country's most recognized facilities, including MD Anderson Cancer Center, the Cleveland Clinic and Memorial Sloan-Kettering Cancer Center. In June 2011, he received the esteemed American Society of Clinical Oncology (ASCO) Statesman Award. Presented annually, the Statesman Award recognizes individual ASCO members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years. Dedicated to finding new and innovative ways to treat cancer, Dr. Markman has published more than 1400 articles, editorials, peer-reviewed manuscripts, book chapters, reviews, letters and abstracts. He has also written or co-edited 10 books and served as an editorial board member on over 40 journals. He is currently Editor-in-Chief of numerous oncology journals, including Oncology Digest and Current Oncology Reports. He is also a Fellow of the American College of Physicians and the American Society of Clinical Oncology. Dr. Markman is regularly listed as one of the “Best Doctors in America” by Best Doctors, Inc., one of “America’s Top Doctors” by Castle Connelly Medical Ltd., and one of “America’s Top Oncologists” by Consumer’s Research Council of America. In 1999 he was recognized as the Lee and Jerome Burkons Research Chair in Oncology by the Cleveland Clinic.
stefan gluck
Stefan Glück
Stefan leads early stage development of solid tumors and immuno-oncology in one of the largest the pharmaceutical companies. Stefan was the Sylvester Professor at the Miller School of Medicine at the University of Miami in Florida. From 2003–2008, he was the Clinical Director of the Braman Family Breast Cancer Institute. Before his move to Miami, Dr. Glück was Director, Southern Alberta Breast Cancer Program at the Tom Baker Cancer Center, and a Professor in the departments of oncology, medicine, pharmacology and therapeutics at the University of Calgary in Alberta, Canada, and Deputy Head, Department of Oncology at the University of Calgary. Dr. Glück was presented the America’s Top Oncologists award from Consumers’ Research Council of America. He was also recognized as one of the Best Doctors in America from 2006 through 2012. He has authored or co-authored more than 200 articles. In addition, Dr Glück has written or co-written a number of book chapters and numerous journal abstracts, and he has presented more than 350 papers at national and international meetings.
Edgardo Santos
Edgardo Santos
Edgardo practices at the Center for Hematology-Oncology (CHO) and is an Associate Professor of Clinical Biomedical Sciences at Florida Atlantic University, and Vice Chairman of the FLASCO Membership Committee. He earned his M.D. in 1994 at the University of Panama, School of Medicine, Republic of Panama. Dr. Santos completed his internship and residency training in Internal Medicine at Jackson Memorial Medical Center, University of Miami School of Medicine, Miami, Florida. Then, he went on to complete his fellowship in Hematology/Oncology at the Sylvester Comprehensive Cancer Center, Miami, Florida. Dr. Santos has authored or co-authored several manuscripts in peer-reviewed journals and also serves as reviewer for several scientific publications. Dr. Santos is a member of the Editorial Board of Expert Review series, Recent Patents on Biomarkers, and Clinical Practice. He has lectured mostly on topics related to lung and head and neck cancers as well as lymphoproliferative disorders and multiple myeloma. Dr. Santos’ main interests are the conduction and development of early phases of clinical trials. Furthermore, he has recently been selected by The International Association of HealthCare Professionals (IAHCP) to be published in the premier publication of The Leading Physicians of the World.

Partners in the US

Thomson Reuters
Structured data on drugs, biomarkers, and clinical trials
Thomson Reuters' Clinical Genomics Toolkit is an important source of information, feeding our web-based curation platform with the latest molecular profiling tests, upcoming drugs, biomarkers and clinical trials.
Washington University in Saint Louis
Knowledge base development and precision oncology toolkits
Massive Bio works closely with Dr. Li Ding at the McDonnell Genome Insitute in Saint Louis, developing databases and web interfaces to educate oncologists on how to interpret complex molecular profiles into patient-friendly content.
Advocacy group for molecular oncology services
Malecare is a men’s cancer survivor support and advocacy group, offering Massive Bio's Molecular Oncology Advisory service to their prostate cancer patients. The partnership has created further awareness of the value added by molecular profiling, especially in late stage treatment settings where standards of treatment are not well defined.
Redox Engine
Interoperate with multiple health IT systems
Health IT systems traditionally have differences that make it difficult to easily exchange information. By linking to each hospital's raw HL7 formatted data, and translating it into a standardized nomenclature, Redox enables Massive Bio to build a Virtual Tumor Board that works with multiple hospitals.
Critical Outcome Technologies
Simulating cancer cells to shortlist effective treatments
Creators of ROSALIND, a dynamic, programmable computer simulation of mutated cancer cell signaling pathways. ROSALIND helps determine which drugs are most likely to be effective at restoring normal cell function. This patented technology provides one of the algorithms Massive Bio uses to shortlist personalized cancer treatment options, before expert review by our Virtual Tumor Board.
Mount Sinai Icahn School of Medicine
Vendor neutral evaluation of molecular profiling reports
In collaboration with Dr. Zeynep Gumus and her lab at the Icahn Institute of Genetics and Genomic Sciences, Massive Bio performs vendor-neutral evaluations of molecular profiling technologies. They also conduct ongoing surveys with oncologists and patients on how to make molecular profile reports intuitive and insightful to treatment strategies.
State-of-the-art technology platform
By leveraging SecondOpinionExpert’s cutting edge information technology and network of top medical experts and Massive Bio’s world-class multidisciplinary cancer team of medical oncologists, molecular diagnostic scientists, reimbursement experts and data scientists, the partnership will make precision oncology accessible, affordable and personalized for patients around the globe. 
B4CC – Before Cancer Cure
Clinical network providing cancer patients with personalized therapies
A substantial portion of community based oncologists have limited access to advancements in molecular diagnostic and genomic therapies for their critically ill patients. Massive Bio and B4CC joins forces to inform cancer patients and their clinicians of relevant targeted therapies and clinical trials.
War Memorial Hospital Massive Bio
War Memorial Hospital has served communities for more than 100 years and employs more than 880 individuals who are deeply committed to delivering patient-focused care.
Hematology Oncology Associates of Palm Beach
Hematology Oncology Associates was established in Palm Beach County over 35 years ago, and has grown to include 7 Board Certified Hematologist and Oncologists in 3 convenient locations.

Partners Outside the US

Anadolu Saglik Group
Anadolu Medical Center provides healthcare services to patients from 30 countries in a most comprehensive and modern way. Massive Bio reviews complex cases of Anadolu Center’s network who doesn’t have the time and money to come to the large cancer centers in US but still wants to get second opinion.
Remed Assistance
Remed Assistance operates in Europe, Middle East and all around the world to provide value added medical tourism, health and insurance services to its clients from various sectors. Massive Bio expands its outreach by leveraging Remed Assistance’s vast international insurer network.
Onko Kocsel
Onko Koçsel Pharmaceuticals has first taken its place in the pharmaceutical sector in 1987 by introducing blood derivative products in Turkey and becoming an exclusive distributor for the reputable European companies such as Caris Life Sciences Europe. Onto Koçsel is a channel partner of Massive Bio; uses its local sales force to train local oncologists in Massive Bio products and benefits of precision oncology.
Intergen Genetic Diagnosis Center
Intergen conducts more than 1,500 varieties of genetic testing; Massive Bio is a channel partner of Intergen to provide tumor board services for already profiled patients.
Neolife Medical Center
Neolife is a leader on the medical services market in Romania, in the oncological field, and one of the reference clinics for healthcare services in Central and Eastern Europe. Neolife and Massive Bio joined forces to support advanced staged cancer patients that require extensive treatment analysis provided by experts from the US.
Genomize is a young, dynamic and fast-growing biotech-startup specialized on genome-level data production and analysis. The company delivers years of bioinformatics know-how for project specific needs in Pharma or Academia.
Egypt Assistance Massive Bio
Egypt Assistance provides a wide range of services to its clients from various sectors in Egypt, UAE, Tunisia and Morocco.
To speak with a dedicated cancer care specialist, contact us: